Biocon targets launching generic Wegovy in India and Canada by 2027, tapping the fast-growing global obesity drug market.

• Biocon to submit India approval request by 2026, with late-stage trials ending in 12–18 months, CEO confirms.
• Canadian filings underway for Ozempic generics; Wegovy filings expected later this year, pending regulatory nod.
• Focus expands to Brazil, Mexico, the Middle East, Australia, and more, using local partnerships for market access.